Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Alvimopan

FDA-approved product (capsule, oral), marketed as Alvimopan, Entereg.

Registered studies
26
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Alvimopan
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Constipation

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Peripheral opioid receptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

26registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Alvimopan in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Alvimopan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy

    NCT00708201 · start 2009-03

    Registered record
    Registry ID
    NCT00708201
    Conditions
    Postoperative Ileus
    Interventions
    Alvimopan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-03
    Completion
    2012-01
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Ileus
    InterventionAlvimopan; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid

    NCT00331045 · start 2006-04

    Registered record
    Registry ID
    NCT00331045
    Conditions
    Cancer; Constipation
    Interventions
    alvimopan; Placebo; Alvimopan 0.5 mg/day; Alvimopan 1 mg/day
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2006-04
    Completion
    2006-12
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Constipation
    Interventionalvimopan; Placebo; Alvimopan 0.5 mg/day; Alvimopan 1 mg/day
    PhasePhase 2
    Registry statusTerminated

  • Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

    NCT00241722 · start 2005-08-01

    Registered record
    Registry ID
    NCT00241722
    Conditions
    Bowel Dysfunction; Constipation
    Interventions
    Alvimopan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-08-01
    Completion
    2007-02-01
    Enrolment
    805

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBowel Dysfunction; Constipation
    InterventionAlvimopan; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

    NCT00256932 · start 2005-08

    Registered record
    Registry ID
    NCT00256932
    Conditions
    Bowel Dysfunction; Constipation
    Interventions
    alvimopan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-08
    Completion
    2006-05
    Enrolment
    518

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBowel Dysfunction; Constipation
    Interventionalvimopan; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

    NCT00259922 · start 2005-08

    Registered record
    Registry ID
    NCT00259922
    Conditions
    Bowel Dysfunction; Constipation
    Interventions
    Placebo; Alvimopan; Alviompan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-08
    Completion
    Not recorded
    Enrolment
    485

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBowel Dysfunction; Constipation
    InterventionPlacebo; Alvimopan; Alviompan
    PhasePhase 3
    Registry statusCompleted

  • Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

    NCT00135577 · start 2004-09

    Registered record
    Registry ID
    NCT00135577
    Conditions
    Cancer; Bowel Dysfunction
    Interventions
    alvimopan; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-09
    Completion
    2007-04
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Bowel Dysfunction
    Interventionalvimopan; placebo
    PhasePhase 2
    Registry statusCompleted

  • Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus

    NCT00205842 · start 2004-06

    Registered record
    Registry ID
    NCT00205842
    Conditions
    Ileus
    Interventions
    alvimopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-06
    Completion
    2005-12
    Enrolment
    660

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIleus
    Interventionalvimopan
    PhasePhase 3
    Registry statusCompleted

  • Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

    NCT00101998 · start 2003-10-01

    Registered record
    Registry ID
    NCT00101998
    Conditions
    Constipation; Bowel Dysfunction
    Interventions
    alvimopan; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-10-01
    Completion
    2006-05-01
    Enrolment
    233

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConstipation; Bowel Dysfunction
    Interventionalvimopan; placebo
    PhasePhase 2
    Registry statusCompleted

  • Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus

    NCT00388401 · start 2002-01

    Registered record
    Registry ID
    NCT00388401
    Conditions
    Ileus
    Interventions
    Alvimopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-01
    Completion
    2003-06
    Enrolment
    510

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIleus
    InterventionAlvimopan
    PhasePhase 3
    Registry statusCompleted

  • Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/ Postoperative Ileus

    NCT00388479 · start 2001-12

    Registered record
    Registry ID
    NCT00388479
    Conditions
    Ileus
    Interventions
    Alvimopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-12
    Completion
    2003-11
    Enrolment
    666

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIleus
    InterventionAlvimopan
    PhasePhase 3
    Registry statusCompleted

  • Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus

    NCT00388258 · start 2001-03-01

    Registered record
    Registry ID
    NCT00388258
    Conditions
    Ileus
    Interventions
    Alvimopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-03-01
    Completion
    2002-12-01
    Enrolment
    451

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIleus
    InterventionAlvimopan
    PhasePhase 3
    Registry statusCompleted